Holen Sie sich die Stockscreener-App
10.20
0.05%
-0.005
Vorhandelsmarkt:
10.70
0.505
+4.95%
Schlusskurs vom Vortag:
$10.20
Offen:
$10.18
24-Stunden-Volumen:
42,187
Relative Volume:
0.47
Marktkapitalisierung:
$341.54M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.05%
1M Leistung:
+0.64%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.18
$10.20
1-Wochen-Bereich:
$10.17
$10.20
52-Wochen-Spanne:
$9.96
$10.27
Drugs Made In America Acquisition Corp Stock (DMAA) Company Profile
Firmenname
Drugs Made In America Acquisition Corp
Sektor
Branche
Telefon
954-870-3104
Adresse
2 PELICAN DR., FORT LAUDERDALE
Vergleichen Sie DMAA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
DMAA
Drugs Made In America Acquisition Corp
|
10.20 | 341.54M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
5.76 | 1.91B | 2.82B | -191.60M | -407.10M | -0.6794 |
|
AACT
Ares Acquisition Corporation Ii
|
11.31 | 702.73M | 0 | 16.92M | -1.35M | 0.29 |
|
CCCM
Columbus Circle Capital Corp I
|
10.52 | 480.62M | 0 | 0 | 0 | 0.00 |
|
EQV
Eqv Ventures Acquisition Corp
|
10.53 | 468.90M | 0 | 0 | 0 | 0.00 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.83 | 465.53M | 0 | 1.30M | 0 | 0.0301 |
Drugs Made In America Acquisition Corp Aktie (DMAA) Neueste Nachrichten
Layoff Tracker: National Resilience Closes 60% of Its Manufacturing Footprint - BioSpace
Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - TradingView
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology - Yahoo Finance
Trump says he is doubling tariffs on imported steel to 50% – as it happened - The Guardian
Pfizer Inc. - Britannica
Drugs Made In America Faces 10-Q Filing Delay - TipRanks
PCI Pharma Services Completes Ajinomoto Althea Acquisition - Contract Pharma
Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges - Business Wire
Financial Snapshot: Analyzing East West Bancorp, Inc (EWBC)’s Key Ratio Metrics - DWinneX
Metric Deep Dive: Understanding Drugs Made In America Acquisition Corp (DMAA) Through its Ratios - DWinneX
Market Resilience: Four Corners Property Trust Inc (FCPT) Finishes Weak at 27.86, Down -1.90 - DWinneX
Daily Progress: Coca-Cola Europacific Partners Plc (CCEP) Drop -0.78, Closing at 88.15 - DWinneX
Financial Analysis: Bio-Key International Inc (BKYI)’s Ratios Unveil Key Insights - DWinneX
Ratio Revelations: Amerant Bancorp Inc (AMTB)’s Financial Metrics in the Spotlight - DWinneX
Closing Strong: Lulus Fashion Lounge Holdings Inc (LVLU) Ends at 0.41, Down -7.73 from Last Close - DWinneX
What's Next for Pfizer After the Company Pulls Its Weight Loss Drug? - Yahoo Finance
The top 20 pharma companies by 2024 revenue - Fierce Pharma
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
WEBTOON Entertainment Inc. (NASDAQ:WBTN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Q1 2025 SPAC Market Update & Outlook - Business Wire
Theratechnologies’ stock soars on disclosure of acquisition offer by U.S. company - Montreal Gazette
Pharma’s US manufacturing moment: Where companies are making the biggest moves - Pharma Voice
10 Best Health Care Stocks to Buy for 2025 - US News Money
After saying overseas drugmakers would have a “big tax to pay,” Trump spares pharmaceuticals from reciprocal tariffs - Sherwood News
'I bought their dream': How a US company's huge land deal in Senegal went bust - Yahoo
Drugs Made In America Acquisition Corp. (DMAA) reports earnings - Quartz
Bright Green Unveils Massive $2B Cannabis Strategy with Zero Shareholder Dilution - StockTitan
Bright Green Corporation Announces the next steps for the completion of its restructuring plan - The Manila Times
How TD Became America’s Most Convenient Bank for Money Launderers - Bloomberg.com
DRUGS MADE IN AMERICA ACQUISITION CORP- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
India-based Syngene acquires its first US biologics site - Manufacturing Dive
Drugmakers Mallinckrodt and Endo get a bump from tariffs in $6.7 billion merger - Reuters
7 Best Weight Loss Drug Stocks to Buy in 2025 | Investing | U.S. News - U.S News & World Report Money
Not All Generics Are Created Equal: Study Exposes a 54% Higher Risk in Indian-Made Drugs - SciTechDaily
Brokerages Set TWFG, Inc. (NASDAQ:TWFG) Target Price at $31.86 - Defense World
BridgeBio Oncology Therapeutics (BBOT) and Helix Acquisition Corp. II Announce Business Combination Agreement to Create Publicly Listed Biotechnology Company Advancing a Pipeline of RAS and PI3Kα-Targeting Medicines - Business Wire
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company - Eli Lilly
A little-known Chinese company made a drug that beat the world’s biggest-selling medicine - CNN
Drugs Made in America Acquisition Corp. Forms Advisory Team to Pursue Pharmaceutical Business Acquisitions - Nasdaq
How Vivek Ramaswamy got rich before going into politics - Cincinnati Enquirer
Popular cannabis brand declares Chapter 11 bankruptcy - TheStreet
Fierce Pharma Asia—Novo Nordisk's fraud accusation; AstraZeneca's China deal; Ono's FDA nod - Fierce Pharma
Drugs Made In America Acquisition Corp. Announces Trading Options for Public Offering Units Starting February 25, 2025 - Nasdaq
Mink Ventures Completes Acquisition of Warren Ni, Cu, Co Patents - The Manila Times
Drugs Made In America Acquisition Corp. Announces Closing of Full Exercise of IPO Over-Allotment Option - TradingView
Drugs Made In America Acquisition Corp. Secures Additional $30 Million in IPO as Underwriter Fully Exercises Overallotment Option - Nasdaq
U.S. investors, Big Pharma race to find new medicines in China - CNBC
Drugs Made In America Acquisition Corp.’s $200 Million Initial Public Offering - Global Legal Chronicle
Finanzdaten der Drugs Made In America Acquisition Corp-Aktie (DMAA)
Es liegen keine Finanzdaten für Drugs Made In America Acquisition Corp (DMAA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
2.43%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):